Aardvark Therapeutics, Inc. Common Stock (AARD) vs Definitive Healthcare Corp. (DH)
A side-by-side comparison of Aardvark Therapeutics, Inc. Common Stock and Definitive Healthcare Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AARD
Aardvark Therapeutics, Inc. Common Stock
$5.10HealthcareDelayed quote: Oct 6, 2026, 12:53 PM EDT
DH
Definitive Healthcare Corp.
$1.00HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
Total return — AARD vs DH
growth of $100 · dividends reinvested · last 2yAARD -63.5% (-39.6%/yr)DH -81.2% (-56.6%/yr)AARD compounded faster over this window
AARD DH
AARD vs DH: by the numbers
- •AARD is the larger company ($112M vs $105M market cap).
- •Both run net losses; AARD's is the smaller (0.00% vs -72.28% net margin).
Metrics side by side
Valuation
| Metric | AARD | DH |
|---|---|---|
| Forward P/E | N/A | 5.13 |
| P/S ratio | N/A | 0.45 |
| P/B ratio | 1.49 | 0.73 |
| EV / EBITDA | N/A | 0.49 |
| FCF yield | N/A | 27.09% |
Profitability
| Metric | AARD | DH |
|---|---|---|
| Gross margin | 0.00% | 71.67% |
| Operating margin | 0.00% | -8.52% |
| Net margin | 0.00% | -72.28% |
| ROE | -93.44% | -116.28% |
| ROIC | -97.99% | 41.64% |
Growth (annualized)
| Metric | AARD | DH |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 10.62% |
| FCF CAGR (5Y) | N/A | 2.14% |
| Total return CAGR (5Y) | N/A | -52.54% |
Go deeper
Dig into the metrics
Aardvark Therapeutics, Inc. Common Stock ROEDefinitive Healthcare ROEAardvark Therapeutics, Inc. Common Stock operating marginDefinitive Healthcare operating marginAardvark Therapeutics, Inc. Common Stock revenue growthDefinitive Healthcare revenue growthAardvark Therapeutics, Inc. Common Stock free cash flowDefinitive Healthcare free cash flow
Aardvark Therapeutics, Inc. Common Stock & Definitive Healthcare appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.